Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 221
Appendix E.5 Rusnano and Other Russian Investors Rusnano is a Russian state-owned equity and venture capital fund. It was set up in 2007 as a state-owned corporation with an investment level of $9 billion, but reorganized in 2011 as a joint-stock company. It has a mandate to develop the nanotech industry in Russia by investing in companies in order to develop and commercialize nanotech-based products in Russia with the goal of nanotech sales reaching $40 billion by 2015. As of June 2012, approximately 20 percent of the funds were to be directed to projects in the life sciences. Investments and commitments by Rusnano and other Russian investors in biotech activities have been announced as follows: 1: Investments in Venture Funds by Russian Organizations: Venture Fund/ Location/Investor/Fund Value Domain Associates/U.S./Rusnano (50%)/$760 million Burrill Capital Fund IV/U.S./Rusnano (40%)/$500 million Maxwell Biotech/U.S.-Russia/Russian Venture Company/$100 million RVC Intrafund/Russia/Russian Venture Company/$68 million RVC Biofund/Russian Venture Company/$50 million 2: Russian Investments in Companies: Company/Location/Investor/Commitment ProBonoBil U.K./Russia/Rusnano/$300 million Nearmedic Plus/Russia/Rusnano/$41 million Magnisense/France/Rusnano/$38 million SynBio/Russia/Rusnano/$31 million Panacela Laboratories/U.S./Rusnano/$26 million 221
OCR for page 221
222 APPENDIX E.5 BIND Biosciences/U.S./Rusnano/$25 million Selecta Biosciences/U.S./Rusnano/$25 million BIOptics/U.S./Rusnano/$5 million CardioNova/Russia/Maxwell Biotech/$1–5 million Hepatera/Russia/Maxwell Biotech/$1–5 million Infectex/Russia/Maxwell Biotech/$1–5 million MetaMax/Russia/Maxwell Biotech/$1–5 million EXAMPLES OF ACTIVITIES OF SPECIAL INTEREST TO RUSNANO: BIND Biosciences (Cambridge, Mass.): Development in Russia of therapeutic nanoparticles for use in addressing solid tumors, inflammatory, and cardiovas- cular diseases. http://www.bindbio.com/content/pages/company/aboutrussia.jsp Selecta Biosciences (Watertown, Mass.): Development in Russia of synthetic vac- cine nanoparticles that encapsulate adjuvant and either a T-cell epitope or allergen in a polylactic acid-co-glycolic acid core surrounded by a lipid monolayer and a PEG shell decorated with a B-cell epitope. Panacela Labs (Buffalo, N.Y.): A 4-year venture between Rusnano ($9 million) and Cleveland BioLabs ($3 million) for an oncology subsidiary. BiOptix Diagnostics (Boulder, Colo.): Development of a surface plasmon- enhanced interferometer-detector for label-free bioassays. http://cen.acs.org/articles/90/i16/Russian-Investors-Bankroll-biotech.html?h= 1167136384. Accessed July 7, 2012.